Table B2.

Therapeutic Breakout 2 Levodopa

Most symptomatically efficacious antiparkinsonian drug
Virtually all PD patients respond
Improves disability and prolongs capacity to maintain employment and independent activities of daily living
May improve mortality rate
Majority develop adverse events
Dyskinesia: choreiform movements, dystonia
Motor fluctuations
Neuropsychiatric problems: confusion, psychosis
Does not treat all features of PD, such as freezing, postural instability, autonomic dysfunction, and dementia
Does not stop disease progression
Theoretically, oxidative metabolites may accelerate disease progression